Regression of left ventricular hypertrophy following angiotensin II receptor blockade: Valsartan in left ventricular hypertrophy

Cardiovascular Reviews and Reports

Volumn 21, Issue 2, 2000, Pages 70-73

  Thürmann, Petra A ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033912615     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens. 1998;16:715-723.
2. Devereux RB, Pini R, Aurigemma GP, et al. Measurement of left ventricular mass: Methodology and expertise. J Hypertens. 1997;15:801-809.
3. Levy D, Garrison RJ, Savage DD, et al. Prognostic, implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990,322:1561-1566.
4. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol. 1996; 78 197-202.
5. Aronow WS, Ahn C, Kronzon I, et al. Association of plasma renin activity and echocardiographic left ventricular hypertrophy with frequency of new coronary events and new atherothrombotic brain infarction in older persons with systemic hypertension. Am J Cardiol. 1997;79:1543-1545.
6. Thürmann PA. Left ventricular and microvascular hypertrophy in essential hypertension: Clinical relevance and prognostic implications. Int J Clin Pharmacol Ther. 1997;35: 181-187.
7. Messerli FH. Clinical determinants and consequences of left ventricular hypertrophy. Am J Med. 1983;75:51-56.
8. Sihm I, Søgaard P, Schroeder AP, et al. Myocardial ischemia and ventricular arrhythmias in relation to left ventricular mass and resistance artery structure. Cardiology. 1997;88:141-146.
9. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
10. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long term antihypertensive treatment. J Hypertens. 1995;13: 1091-1095.
11. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950-1989. N Engl J Med. 1999;340:1221-1227.
12. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. Meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
13. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
14. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-2014.
15. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation. 1995;91:698-706.
16. Miyata S, Haneda T, Osaki J, et al Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells. Eur J Pharmacol 1996;307.81-88.
17. Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997;77:24-31.
18. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265: 2348-2357.
19. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649-1654
20. 1-receptor blockade. Cardiovasc Res. 1996;31:758-768.
21. Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular rats. Effect of losartan and spironolactone Hypertension. 1995;26:101-111.
22. Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996;23:576-578.
23. Markham A. Goa KL. Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54:299-311.
24. Devereux RB, Dahlof B. Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994;8:735-739.
25. Philipp T, Anlauf M, Distler A, et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study. BMJ. 1997,315:154-159.
26. Thürmann PA, Stephens N, Heagerty AM, et al. Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Hypertension 1996;28:450-456.
27. Sahn DJ, DeMaria A, Kisslo J, et al Recommendations regarding quantitation in m-mode echocardiography: Results of a survey of echocardiographic measurements Circulation. 1978;58:1072-1083.
28. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
29. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997;349:1743-1744.
30. Himmelmann A, Svensson A, Bergbrant A, et al. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens. 1996;10:729-734.
31. Tedesco MA, Ratti G, Aquino D, et al. Effects of losartan on hypertension and left ventricular mass: A long-term study. J Hum Hypertens. 1998,12:505-510.
32. Kahan T, Malmqvist K, Edner M, et al. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and beta-blockade. J Am Coll Cardiol 1998;31:258C.
33. Schulte K-L. Meyer-Saballek W, Liederwald K, et al. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term treatment with perindopril versus nifedipine. Am J Cardiol. 1992,70:468-473.
34. Manolis AJ, Beldekos D, Handanis S, et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy. Effects on LVH regression and arrhythmogenic propensity. Am J Hypertens. 1998;11: 640-648.
35. Campbell SV, Rizzo V, Di Maio F, et al. Antihypertensive therapy with losartan and fosinopril. Efficacy in left ventricular hypertrophy regression. Am J Hypertens. 1998;11:125A.
36. Diamond JA, Gharavi A, Machac J, et al. Effect of long term eprosartan versus enalapril antihypertensive therapy on LV mass and coronary flow reserve in stage-II hypertension. Am J Hypertens. 1998;11:72A.
37. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 1994;89: 2204-2211.
38. 1-receptor blockade in human hypertension. Am J Hypertens 1998;11:548-553.
39. 1) blockade reduces ventricular arrhythmias in uncomplicated essential hypertensive patients. Am J Hypertens. 1998;11:40A.
40. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7: 176-183.
41. Dahlöf B. Devereux R, deFaire U, et al, for the LIFE Study Group. Baseline characteristics of the LIFE (Losartan Intervention For Endpoint Reduction) in hypertension study. J Hypertens. 1997;15:S35.
42. Sheridan DJ, Kingsbury MP, Flores NA. Regression of left ventricular hypertrophy: What are appropriate therapeutic objectives? Br J Clin Pharmacol 1999;47:125-130.